Comparison of disease activity measures for ANCA-associated vasculitis.

被引：0
|
作者：
Merkel, PA
Cuthbertson, D
Hellmich, B
Hoffman, GS
Jayne, D
Kallenberg, CGM
Krischer, J
Luqmani, R
Mahr, A
Matteson, EL
Specks, U
Stone, JH
机构：
[1] Boston Univ, Vasculitis Clin Res Consortium, Boston, MA 02215 USA
[2] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
[3] Univ Schleswig Holstein, Lubeck, Germany
[4] Cleveland Clin, Cleveland, OH 44106 USA
[5] Addenbrookes Hosp, Cambridge, England
[6] Univ Groningen Hosp, Groningen, Netherlands
[7] Univ Edinburgh, Edinburgh EH8 9YL, Midlothian, Scotland
[8] Hop Cochin, F-75674 Paris, France
[9] Mayo Clin, Rochester, MN USA
[10] Johns Hopkins Univ, Baltimore, MD 21218 USA
来源：
ARTHRITIS AND RHEUMATISM | 2004年 / 50卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S229 / S230
页数：2
相关论文
共 50 条
  • [1] Comparison of disease activity measures for ANCA-associated vasculitis
    KIDNEY & BLOOD PRESSURE RESEARCH, 2005, 28 (03): : 169 - 170
  • [2] Serum Calprotectin and Disease Relapse in ANCA-Associated Vasculitis.
    Draibe, Juliana B.
    Pepper, Ruth J.
    Merkel, Peter A.
    Salama, Alan D.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S818 - S819
  • [3] Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis.
    Stone, John H.
    Merkel, Peter A.
    Spiera, Robert
    Seo, Philip
    Langford, Carol A.
    Hoffman, Gary S.
    Kallenberg, Cees G. M.
    Clair, E. William St.
    Turkiewicz, Anthony
    Tchao, Nadia K.
    Webber, Lisa
    Ding, Linna
    Sejismundo, Lourdes P.
    Mieras, Kathleen
    Weitzenkamp, David
    Ikle, David
    Seyfert-Margolis, Vicki
    Mueller, Mark
    Brunetta, Paul
    Allen, Nancy B.
    Fervenza, Fernando C.
    Geetha, Duvuru
    Keogh, Karina A.
    Kissin, Eugene Y.
    Monach, Paul A.
    Peikert, Tobias
    Stegeman, Coen
    Ytterberg, Steven R.
    Specks, Ulrich
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (03): : 221 - 232
  • [4] Azathioprine or Methotrexate Maintenance for ANCA-Associated Vasculitis.
    Pagnoux, Christian
    Mahr, Alfred
    Hamidou, Mohamed A.
    Boffa, Jean-Jacques
    Ruivard, Marc
    Ducroix, Jean-Pierre
    Kyndt, Xavier
    Lifermann, Francois
    Papo, Thomas
    Lambert, Marc
    Le Noach, Jose
    Khellaf, Mehdi
    Merrien, Dominique
    Puechal, Xavier
    Vinzio, Stephane
    Cohen, Pascal
    Mouthon, Luc
    Cordier, Jean-Francois
    Guillevin, Loic
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (26): : 2790 - 2803
  • [5] Initial disease activity predicts long term damage in patients with ANCA-associated vasculitis.
    Brijker, F
    Tervaert, JWC
    Murphy, R
    Magee, C
    Mulloy, E
    ONeill, S
    Browne, O
    Campbell, E
    Walshe, J
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1996, 7 (09): : A2622 - A2622
  • [6] Cyclosporine for the prevention of relapses in ANCA-associated vasculitis.
    Haubitz, M
    Koch, KM
    Brunkhorst, R
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1997, 8 : A0414 - A0414
  • [7] Thyroid Disease in ANCA-associated Vasculitis. a Population-based Study
    Wilding, Anna
    Smith, Rona
    Jayne, David
    Segelmark, Marten
    Mohammad, Aladdin
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [8] Platelet-derived microparticles (PDMPs) is a new marker for disease activity in ANCA-associated vasculitis.
    Susaki, Kentaro
    Dobashi, Hiroaki
    Kittaka, Katsuharu
    Kameda, Tomohiro
    Tokuda, Michiaki
    Ishida, Toshihiko
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S762 - S762
  • [9] Granulomatous ANCA-associated vasculitis. Wegener's granulomatosis
    Wiesner, O.
    Haubitz, M.
    PNEUMOLOGE, 2008, 5 (05): : 308 - 319
  • [10] BIOMARKER OF DISEASE ACTIVITY IN ANCA-ASSOCIATED VASCULITIS
    Neumann, Thomas
    Leierer, Johannes
    Toppmoeller, Tobias
    Kronbichler, Andreas
    RHEUMATOLOGY, 2017, 56 : 125 - 125
12345